Abeona Therapeutics Inc. (ABEO)

Market Cap	19.52M
Revenue (ttm)	4.70M
Net Income (ttm)	-86.60M
Shares Out	5.95M
EPS (ttm)	38.68
PE Ratio	0.08
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	460,408
Open	3.10
Previous Close	3.04
Day's Range	3.01 - 3.34
52-Week Range	0.27 - 27.75
Beta	1.08
Analysts	Buy
Price Target	15.98 (+387.2%)
Earnings Date	Nov 14, 2022

About ABEO

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorder...

• Industry: Biotechnology
• IPO Date: Sep 19, 1980
• CEO: Joao Siffert
• Employees: 90
• Stock Exchange: NASDAQ
• Ticker Symbol: ABEO

Full Company Profile

Financial Performance

In 2021, ABEO's revenue was $3.00 million, a decrease of -70.00% compared to the previous year's $10.00 million. Losses were -$84.94 million, 0.83% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ABEO stock is "Buy." The 12-month stock price forecast is 15.98, which is an increase of 387.20% from the latest price.

Price Target

$15.98

(387.20% upside)

Analyst Consensus: Buy

Stock Forecasts